EnteroBiotix Limited
Corporate brand
UnclaimedEnteroBiotix is a clinical-stage UK microbiome therapeutics company developing orally delivered, full-spectrum microbiome drugs such as EBX-102-02 for IBS and other gastrointestinal and liver diseases.
Last updated September 26, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
EnteroBiotix Limited is a clinical-stage biopharmaceutical company based in Bellshill, United Kingdom, focused on the development of microbiome-modulating therapeutics for gastrointestinal and liver diseases. The company describes its mission as transforming the standard of care for patients with gastrointestinal disease, and it positions itself as "orchestrating gut health." Its lead investigational product, EBX-102-02, is an orally administered, full-spectrum microbiome drug candidate being evaluated in clinical studies for irritable bowel syndrome (IBS) and other diseases linked to the gastrointestinal tract and the liver. EBX-102-02 is described by the company as a high-diversity microbial product formulated as an off-white, odourless powder and manufactured using EnteroBiotix's proprietary AMPLA drying technology. The formulation is designed to be refrigerator-stable and suitable for scalable manufacture, and it is protected by granted composition-of-matter patents. The product is investigational; safety and efficacy have not been established. EnteroBiotix has stated that it secured £19 million to initiate a Phase 2b clinical trial for IBS, reflecting its progression into later-stage clinical development. The company is led by an entrepreneurial and experienced management team, supported by a Board of Directors and a Scientific Advisory Board. Dr James McIlroy, a qualified medical doctor, serves as CEO and board member and is credited with forming the company, raising approximately £55 million, establishing technology platforms, and initiating and completing Phase 2 clinical trials with positive data. The executive team also includes Dr James Barnes as COO and Melissa Strange as CFO. The Board includes Non-Executive Chairman Elmar Schnee, formerly CEO of Merck Serono, alongside investor directors Iain Baird, Mark Bamforth, and Douglas Thomson. The IBS Scientific Advisory Board includes Professor William D. Chey, Professor Eamonn M. M. Quigley, Professor Robin Spiller, and Professor Jan Tack. EnteroBiotix operates in the biotechnology and pharmaceutical sector, with a focus on the gut microbiome as a therapeutic target. The company is privately held and is growing rapidly, recruiting medical professionals, scientists, and pharmaceutical executives. It is an accredited Living Wage Employer and offers an enhanced pension plan, among other benefits. Its activities are centered on clinical development, intellectual property protection, and scalable manufacturing of microbiome-based therapeutics.
History
EnteroBiotix Limited is a clinical-stage microbiome therapeutics company based in Bellshill, United Kingdom. The company was formed by Dr James McIlroy, a qualified medical doctor, who serves as CEO and board member. Under his leadership, EnteroBiotix has raised approximately £55 million, established technology platforms, and initiated and completed Phase 2 clinical trials with positive data. The company's mission is to transform the standard of care for patients with gastrointestinal disease, and it operates under the tagline "Orchestrating gut health." EnteroBiotix focuses on unlocking the therapeutic potential of the gut microbiome through novel microbiome-modulating therapeutics. Its lead investigational product, EBX-102-02, is an orally administered, full-spectrum microbiome drug in clinical development for irritable bowel syndrome (IBS) and other diseases linked to the gastrointestinal tract and the liver. EBX-102-02 is a high-diversity microbial product formulated as an off-white, odourless powder and manufactured using EnteroBiotix's proprietary AMPLA drying technology. The formulation is designed to be refrigerator-stable and suitable for scalable manufacture, and it is protected by granted composition-of-matter patents. The product is currently being evaluated in clinical studies; safety and efficacy have not been established. The company has stated that it secured £19 million to initiate a Phase 2b clinical trial for IBS. IBS is described by EnteroBiotix as one of the largest unmet medical needs in modern medicine, driven by gut dysfunction, microbiome imbalance, and low-grade immune activation. Current treatments are largely symptomatic and do not address underlying microbiome dysbiosis, leading many patients to experience persistent symptoms and limited durable benefit. EnteroBiotix is led by an entrepreneurial and experienced management team, supported by a distinguished Board of Directors and a world-class Scientific Advisory Board. The executive team includes Dr James McIlroy (CEO & Board Member), Dr James Barnes (COO), and Melissa Strange (CFO). The Board of Directors includes Elmar Schnee (Non-Executive Chairman, previously CEO of Merck Serono), Iain Baird (Investor Director), Mark Bamforth (Investor Director), and Douglas Thomson (Investor Director). The IBS Scientific Advisory Board includes Professor William D. Chey, Professor Eamonn M. M. Quigley, Professor Robin Spiller, and Professor Jan Tack. The company is growing rapidly and is always looking for talented, ambitious, collaborative, and adaptable people. It is an accredited Living Wage Employer, committed to paying all employees above the real Living Wage, and offers an enhanced pension plan through salary exchange, matching employee contributions up to 10%. EnteroBiotix is privately held and continues to advance its clinical programs in microbiome therapeutics.
Company formed by Dr James McIlroy
Raised approximately £55 million and established technology platforms
Initiated and completed Phase 2 clinical trials with positive data
Secured £19 million to initiate Phase 2b clinical trial for IBS
Products and positioning
Clinical-stage microbiome therapeutics company advancing orally delivered, full-spectrum microbiome drugs for gastrointestinal and liver diseases.
EBX-102-02
An investigational, orally administered, full-spectrum microbiome-based therapeutic under clinical development for irritable bowel syndrome (IBS) and other diseases linked to the gastrointestinal tract and the liver. It is a high-diversity microbial product formulated as an off-white, odourless powder and manufactured using EnteroBiotix's proprietary AMPLA drying technology. The formulation is designed to be refrigerator-stable and suitable for scalable manufacture, and is protected by granted composition-of-matter patents.
Recent events
Sources5 sources
Cite this profile: Cite the canonical profile. /brand-wiki/enterobiotix-limited-united-kingdom · Editorial policy · How profiles are compiled